Biogen MS drug could be first-choice treatment-U.S. panel
GAITHERSBURG, Maryland (Reuters) – Biogen Idec and Elan’s
multiple sclerosis drug Tysabri could be used as a first-choice
treatment for some patients if it returns to the market, a U.S.
advisory panel said on Wednesday.
The committee voted 7-5 in favor of Tysabri as an initial
treatment for some patients.
The panel was due to vote later Wednesday on whether to
recommend resumed sales for the drug, which was pulled from the
market in February 2005 after three patients developed a
life-threatening brain infection and two of them died.